Neos Therapeutics (NASDAQ:NEOS) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday, February 17th.
Several other research firms have also issued reports on NEOS. Cowen restated a “buy” rating on shares of Neos Therapeutics in a research report on Thursday, October 26th. Cantor Fitzgerald set a $20.00 price target on shares of Neos Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, November 1st. BMO Capital Markets lowered shares of Neos Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 31st. Finally, Zacks Investment Research lowered shares of Neos Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 25th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. Neos Therapeutics has an average rating of “Hold” and a consensus price target of $14.00.
Neos Therapeutics (NASDAQ NEOS) traded up $0.10 during midday trading on Friday, reaching $8.90. 351,958 shares of the company’s stock traded hands, compared to its average volume of 326,105. The company has a quick ratio of 2.14, a current ratio of 2.42 and a debt-to-equity ratio of 4.01. The firm has a market cap of $260.97, a price-to-earnings ratio of -2.60 and a beta of -0.20. Neos Therapeutics has a 52 week low of $6.30 and a 52 week high of $13.15.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://stocknewstimes.com/2018/03/14/neos-therapeutics-neos-downgraded-by-bidaskclub.html.
Neos Therapeutics Company Profile
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.